Interferon-beta (IFN-beta) is one of the most widely prescribed medications for relapsing-remitting multiple sclerosis (RRMS). IFN-related thrombotic microangiopathy (TMA) is a rare but severe complication, with a fulminant clinical onset and a possibly life-threatening outcome that may occur years after a well-tolerated treatment with IFN. Most patients evolve rapidly to advanced chronic kidney disease and eventually to renal failure.

Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab / Allinovi, Marco; Cirami, Calogero Lino; Caroti, Leonardo; Antognoli, Giulia; Farsetti, Silvia; Amato, Maria Pia; Minetti, Enrico Eugenio. - In: CLINICAL KIDNEY JOURNAL. - ISSN 2048-8505. - STAMPA. - 10:(2017), pp. 625-631. [10.1093/ckj/sfw143]

Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab

ALLINOVI, MARCO;CAROTI, LEONARDO;ANTOGNOLI, GIULIA;FARSETTI, SILVIA;AMATO, MARIA PIA;
2017

Abstract

Interferon-beta (IFN-beta) is one of the most widely prescribed medications for relapsing-remitting multiple sclerosis (RRMS). IFN-related thrombotic microangiopathy (TMA) is a rare but severe complication, with a fulminant clinical onset and a possibly life-threatening outcome that may occur years after a well-tolerated treatment with IFN. Most patients evolve rapidly to advanced chronic kidney disease and eventually to renal failure.
2017
10
625
631
Allinovi, Marco; Cirami, Calogero Lino; Caroti, Leonardo; Antognoli, Giulia; Farsetti, Silvia; Amato, Maria Pia; Minetti, Enrico Eugenio
File in questo prodotto:
File Dimensione Formato  
sfw143.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 547.04 kB
Formato Adobe PDF
547.04 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1096937
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 21
social impact